Celldex Therapeutics SVPs Engage In Heavy Transactions

6 days ago 3

Adé Hennis, The Motley Fool

Mon, January 12, 2026 astatine 9:54 AM CST 5 min read

Freddy A. Jimenez straight sold 4,166 shares for a transaction worth of $121,210 connected Dec. 4, 2025.
This transaction represented 11.92% of his nonstop holdings astatine the time, reducing his nonstop involvement from 34,962 to 30,796 shares.
The merchantability was executed wholly successful nonstop ownership, with nary engagement of indirect entities oregon derivative securities.
These 10 stocks could mint the adjacent question of millionaires ›

On Dec. 4, 2025, Freddy A. Jimenez, Senior Vice President & General Counsel of Celldex Therapeutics (NASDAQ:CLDX), executed an open-market merchantability of 4,166 insider shares. See SEC Form 4 filing.

Metric

Value

Shares sold (direct)	4,166
Transaction value	$121,210
Post-transaction shares (direct)	30,796
Post-transaction worth (direct ownership)	$895,856

Transaction worth based connected SEC Form 4 reported terms ($29.09); post-transaction worth based connected Dec. 4, 2025 marketplace adjacent ($29.09).

How does the size of this merchantability comparison to Jimenez's humanities selling activity?
This merchantability of 4,166 shares is larger than his lone different caller open-market merchantability (771 shares connected Aug. 13, 2025) and exceeds the caller median merchantability size of 2,468 shares.
What proportionality of Jimenez's full equity involvement was affected by this transaction?
The merchantability reduced his nonstop ownership by 11.92%, leaving him with 30,796 shares and nary indirect holdings arsenic of Dec. 8, 2025.

Metric

Value

Market capitalization	$1.82 Billion
Revenue (TTM)	$2.60 million
Net income (TTM)	-$224.53 million
*1-year terms change	-0.26%

* 1-year terms alteration calculated utilizing Jan. 12, 2025 arsenic the notation date.

Celldex Therapeutics develops therapeutic antibodies, with pb objective programs targeting inflammatory diseases and oncology indications.
The institution operates uses a research-driven biopharmaceutical model, focused connected probe collaboration and licence agreements.
It targets healthcare providers, probe institutions, and pharmaceutical partners focused connected innovative treatments for immune-mediated diseases and cancer.

Jimenez wasn’t the lone SVP conducting insider transactions adjacent the opening of 2026. On Dec. 15, 2025, SVP & CBO Pepin Ronald acquired 19,333 shares by exercising 2 antecedently granted banal options. One enactment allowed him to acquisition 8,333 shares astatine a terms of $9.02, portion the different provided him with 11,000 shares astatine an workout terms of $2.78. The full worth of the acquisitions was $105,744.

Then connected Jan. 2, 2026, Martin Samuel Bates, SVP and CFO, besides acquired shares by exercising an option. He acquired 4,817 shares astatine a terms of $10.38, worthy $50,000. It’s unclear wherefore some Ronald and Bates waited years to workout their options, adjacent though they reached their onslaught prices years earlier.